Stock Track | MannKind Soars 7.14% in Pre-Market on Strong Q4 Revenue Growth and Sales Beat

Stock Track

Feb 26

MannKind's stock surged 7.14% in pre-market trading following the release of its fourth quarter financial results that showed strong revenue growth and a significant sales beat.

The company reported Q4 revenue of $112 million, representing a 46% year-over-year increase. More importantly, sales of $111.955 million substantially exceeded analyst estimates of $97.604 million by 14.70%. The company also reported adjusted earnings per share of $0.01, which met consensus expectations.

Business updates included FDA acceptance of an Afrezza pediatric sBLA with a PDUFA date of May 29, 2026, and FDA acceptance of a Furoscix ReadyFlow Autoinjector sNDA with a PDUFA date of July 26, 2026. The company also noted progress in clinical trials for nintedanib DPI and initiated a Phase 2 IPF trial.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1167773891"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1167773891\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1167773891?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 21:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167773891","market":"hk","top_or_hot":-1,"title":"Stock Track | MannKind Soars 7.14% in Pre-Market on Strong Q4 Revenue Growth and Sales Beat","media":"Stock Track","content":"<p>MannKind's stock surged 7.14% in pre-market trading following the release of its fourth quarter financial results that showed strong revenue growth and a significant sales beat.</p><p>The company reported Q4 revenue of $112 million, representing a 46% year-over-year increase. More importantly, sales of $111.955 million substantially exceeded analyst estimates of $97.604 million by 14.70%. The company also reported adjusted earnings per share of $0.01, which met consensus expectations.</p><p>Business updates included FDA acceptance of an Afrezza pediatric sBLA with a PDUFA date of May 29, 2026, and FDA acceptance of a Furoscix ReadyFlow Autoinjector sNDA with a PDUFA date of July 26, 2026. The company also noted progress in clinical trials for nintedanib DPI and initiated a Phase 2 IPF trial.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | MannKind Soars 7.14% in Pre-Market on Strong Q4 Revenue Growth and Sales Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | MannKind Soars 7.14% in Pre-Market on Strong Q4 Revenue Growth and Sales Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-26 21:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MannKind's stock surged 7.14% in pre-market trading following the release of its fourth quarter financial results that showed strong revenue growth and a significant sales beat.</p><p>The company reported Q4 revenue of $112 million, representing a 46% year-over-year increase. More importantly, sales of $111.955 million substantially exceeded analyst estimates of $97.604 million by 14.70%. The company also reported adjusted earnings per share of $0.01, which met consensus expectations.</p><p>Business updates included FDA acceptance of an Afrezza pediatric sBLA with a PDUFA date of May 29, 2026, and FDA acceptance of a Furoscix ReadyFlow Autoinjector sNDA with a PDUFA date of July 26, 2026. The company also noted progress in clinical trials for nintedanib DPI and initiated a Phase 2 IPF trial.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNKD","symbol_name":"曼恩凯德生物医疗","start_time":0,"source_url":"","article_id":"1167773891","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167773891","pubTimestamp":1772111455,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"MannKind's stock surged 7.14% in pre-market trading following the release of its fourth quarter financial results that showed strong revenue growth and a significant sales beat.The company reported...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MNKD":"曼恩凯德生物医疗"},"translate_title":"个股追踪|MannKind盘前大涨7.14%，Q4营收增长强劲，销量超预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":1},"content_text":"MannKind's stock surged 7.14% in pre-market trading following the release of its fourth quarter financial results that showed strong revenue growth and a significant sales beat.The company reported Q4 revenue of $112 million, representing a 46% year-over-year increase. More importantly, sales of $111.955 million substantially exceeded analyst estimates of $97.604 million by 14.70%. The company also reported adjusted earnings per share of $0.01, which met consensus expectations.Business updates included FDA acceptance of an Afrezza pediatric sBLA with a PDUFA date of May 29, 2026, and FDA acceptance of a Furoscix ReadyFlow Autoinjector sNDA with a PDUFA date of July 26, 2026. The company also noted progress in clinical trials for nintedanib DPI and initiated a Phase 2 IPF trial.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}